Title: Characterization of Corynebacterium diphtheriae isolates from infected skin lesions in the Northern Territory of Australia.

Authors: Claire L. Gordon¹*, Peter Fagan², Jann Hennessy², Robert Baird¹²

1. Department of Infectious Diseases, Royal Darwin Hospital, Darwin, Australia
2. Department of Microbiology, Royal Darwin Hospital, Darwin, Australia

Running title: C. diphtheriae in Northern Australia

*Correspondence to: Dr Claire Gordon
Microbiology Department
Royal Darwin Hospital
105 Rocklands Drive
Casuarina NT 0810
Australia
Phone: (618) 8922 8888
Fax: (618) 8922 7788
*Email: Claire.gordon@nt.gov.au

The author’s have no conflicts of interest.
Corynebacterium diphtheriae is commonly isolated from cutaneous skin lesions in the Northern Territory, Australia. We prospectively assessed 32 recent isolates from infected skin lesions, in addition to reviewing 192 isolates collected over five years for toxin status. No isolates carried the toxin gene. Toxigenic C. diphtheriae is now a rare occurrence in the Northern Territory.

Manuscript

Corynebacterium diphtheriae are frequently isolated from cutaneous lesions in tropical areas, including the north of Australia and the central Australian desert (2, 14); geographical areas that are part of the Northern Territory (NT). Toxigenic strains of C. diphtheriae are the causative agent of respiratory diphtheria, but strains of C. diphtheriae isolated from cutaneous lesions can be either toxigenic or non-toxigenic (18), and pathogens or colonisers. Cutaneous diphtheria, caused by toxigenic strains can act as a reservoir for respiratory diphtheria (1, 8). Infections with non-toxigenic C. diphtheriae occur in patients subsisting in low socio-economic conditions regardless of the climate (10, 15, 18).

In the past, toxigenic C. diphtheriae have been isolated from patients living in the NT. In the Central Australian desert, 38% of C. diphtheriae isolates tested over a 7 year period from 1985, were found to be toxigenic by Elek testing (14). The last reported case of locally acquired diphtheria was a fatal respiratory adult case from the north of the NT in 1992 (2). Sporadic cases of cutaneous diphtheria have since occurred, but all have been acquired from outside of Australia (2). For many years, standard laboratory practice in the NT has been to assess all C. diphtheriae isolates for toxin production, however, toxin-producing strains are seldom detected.
This study aimed to detect the current prevalence of toxigenic *C. diphtheriae* strains isolated from clinically infected skin lesions referred to the Royal Darwin Hospital (RDH) Pathology Department. The RDH Pathology Department serves the RDH and is a referral laboratory for the four public microbiology laboratories (Alice Springs [ASH], Katherine, Tennant Creek [TCH], Gove [GDH]) in the NT spread out over 1,300,000 square kilometres. In addition to using molecular methods at RDH to detect the diphtheria toxin encoding gene (*tox*) in our more recent isolates, we retrospectively reviewed all *C. diphtheriae* isolates from clinically infected skin lesions, which had been referred from RDH or the four public microbiology laboratories to the Institute of Medical and Veterinary Sciences (IMVS), Adelaide, for *tox* testing over the last 5 years. The results of the study were used to evaluate the rationale for routine *C. diphtheriae* toxin testing in the NT.

*C. diphtheriae* isolates from clinical specimens submitted to the RDH Pathology Department were prospectively collected over a 5-month period (January to May 2011). Coryneform bacteria were screened using Oxoid tellurite agar (Hoyle’s) and identified with the API (RAPID) Coryne system (bioMérieux, Marcy l’Etoile, France) (4, 20): (i) if isolated from normally sterile body sites; (ii) if they were the predominant organisms from non-sterile clinical material; (iii) if colony growth occurred outside the primary inoculum; or (iv) if Gram-positive bacilli were seen in the direct staining. Other bacterial isolates were identified by conventional and automated microbiological methods.

*C. diphtheriae* cultures for toxin-gene testing were resuspended to 0.5 MacFarlane using 0.45% saline prior to DNA isolation using the MagNA Pure LC total NA isolation protocol as recommended by the manufacturer (Roche). Samples were subsequently tested for the presence of *tox* using a previously described PCR method (19). ATCC 13812 Park Williams 8, gravis *tox*+ (9) was used as the toxigenic positive control.
Thirty-two *C. diphtheriae* isolates were collected from clinically infected skin lesions. *C. diphtheriae* was not isolated from any throat specimens during this period. Microbiological features are shown in Table 1. Bacterial skin co-pathogens such as *Staphylococcus aureus*, *Streptococcus pyogenes* and *Arcanobacterium haemolyticum*, were isolated from every specimen. *A. haemolyticum* (previously a member of corynebacterium group, *C. haemolyticum*) has been previously associated with cutaneous diphtheria isolates (10). Eighteen patients had three skin pathogens isolated; *C. diphtheriae*, *S. aureus* and beta-haemolytic streptococci. The toxin gene was not detected in any of the *C. diphtheriae* isolates.

Two-hundred and nineteen isolates of *C. diphtheriae* were obtained from clinically infected skin lesions over the period from 2005 to 2010; 197 were isolated at RDH, 18 were isolated at ASH, 3 were isolated at GDH and 1 was isolated at TCH. Coryneform bacteria were identified as *C. diphtheriae* using the API (RAPID) Coryne system (bio Mérieux, Marcy l’Etoile, France) (9). The biotypes were as follows; var mitis 127 (58%), var gravis 57 (26%), ambiguous biotype, listed as *C. diphtheriae* 35 (16%). Over the same period, *C. diphtheriae* was isolated from blood cultures taken from 9 patients, and was not isolated from any respiratory specimens. Of the 219 cutaneous *C. diphtheriae* isolates, *tox* testing of 192 isolates was negative. As clinical diphtheria becomes less frequent, laboratories should be aware of the potential for bacterial misidentification (16).

*Corynebacterium diphtheriae* is endemic in the NT and is regularly cultured from infected skin lesions, particularly from indigenous patients. Non-toxigenic *C. diphtheriae* can cause pharyngitis and invasive infection that may be fatal (i.e pneumonia, sepsis, catheter-related infection, endocarditis and osteomyelitis) (6, 21). Historical reports document toxigenic *C. diphtheriae* were endemic in the central Australian desert and the tropical north of Australia as late as the 1990’s (2, 14), while diphtheria has been a rare occurrence in other Australian states following the introduction of the Diphtheria-tetanus-polio vaccine in the 1950’s (12). However, 229 *C.
*diphtheriae* isolates from infected skin lesions from both central Australia and the tropical north of Australia, from the last 5 and a half years were all non-toxigenic. Our results suggest that toxigenic *C. diphtheriae* are now a rare occurrence in the NT.

The reasons for the reduction of tox carrying *C. diphtheriae* strains in the NT are unclear, although it has been postulated that tox may be lost from organisms in highly immunized populations (3). The toxin gene is carried on a bacteriophage but the toxin is a nonessential protein for both the phage or its lysogenic host bacterium (13). The selective advantage arises in clinical diphtheria when the toxin allows rapid and sustained transmission of toxigenic organisms from nasopharyngeal membranes or cutaneous ulcers to non-immune humans (13). Thus, widespread immunization protects against diphtheria and may also reduce transmission of toxigenic strains (13). The current diphtheria vaccination coverage in NT children at 2 years of age is 95.5% (11), and the indigenous rate is similar to the non-indigenous rate (7). A recent case of non-travel associated diphtheria in a partially vaccinated teenager in the United Kingdom highlights the importance of continued vaccination (17). The use of penicillin in rheumatic heart disease and skin sore control programs in North and Central Australian Indigenous communities may also simultaneously treat cutaneous diphtheria, as well as eradicate the carrier state of toxigenic strains, thereby preventing transmission of toxigenic strains.

Although, toxigenic *C. diphtheriae* was not isolated in our study, toxigenic strains continue to circulate in developing countries, including in South Asia, Southeast Asia, Africa and parts of South America (22). Since 1992, the two cases of diphtheria in the NT have occurred in migrants or returned travellers from endemic areas and pre-travel vaccination is recommended (2). A high index of suspicion should be maintained for these high-risk groups and diphtheria toxin testing of *C. diphtheriae* isolates should be performed. In addition, because tox is phage mediated, it is possible that toxigenic *C. diphtheriae* may re-emerge (5) and spread locally if diphtheria immunisation rates...
decline. Based on the findings of this study, our laboratory no longer tests for *C. diphtheriae* toxin routinely.

We would like to thank the RDH Microbiology staff for collecting the *C. diphtheriae* isolates, IMVS for performing tox testing prior to 2011, Deepthi Satheesh for retrieving the *C. diphtheriae* isolate data and Helen V. Smith at Queensland Health Forensic and Scientific Services for her assistance.
Table 1: Microbiological characteristics of *Corynebacterium diphtheriae* isolated from clinically infected skin lesions

<table>
<thead>
<tr>
<th></th>
<th>C. diphtheriae isolates (n=32)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age in years (interquartile range [IQR])</td>
<td>38 (26-48)</td>
</tr>
<tr>
<td>Male (%)</td>
<td>19 (59%)</td>
</tr>
<tr>
<td>Site clinical specimen taken from</td>
<td></td>
</tr>
<tr>
<td>Lower limb</td>
<td>20</td>
</tr>
<tr>
<td>Upper limb</td>
<td>2</td>
</tr>
<tr>
<td>Trunk</td>
<td>4</td>
</tr>
<tr>
<td>Head and neck</td>
<td>4</td>
</tr>
<tr>
<td>Unknown</td>
<td>2</td>
</tr>
<tr>
<td><em>C. diphtheriae</em> biotype</td>
<td></td>
</tr>
<tr>
<td><em>var gravis</em></td>
<td>6</td>
</tr>
<tr>
<td><em>var mitis</em></td>
<td>7</td>
</tr>
<tr>
<td><em>var mitis/belfanti</em></td>
<td>19</td>
</tr>
<tr>
<td>Co-infection with other bacteria</td>
<td>32 (100%)</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em> (methicillin-sensitive)</td>
<td>17</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em> (methicillin-resistant*)</td>
<td>7</td>
</tr>
<tr>
<td><em>Streptococcus pyogenes</em></td>
<td>22</td>
</tr>
<tr>
<td><em>Arcanobacterium haemolyticum</em></td>
<td>8</td>
</tr>
<tr>
<td>Gram negative bacteria only*</td>
<td>11</td>
</tr>
<tr>
<td>Group G streptococci</td>
<td>3</td>
</tr>
</tbody>
</table>

^ All methicillin resistant Staphylococcus aureus isolates were community-associated (21)

^* API (RAPID) Coryne system was not able to differentiate between *C. diphtheriae var mitis* and *C. diphtheriae belfanti*.

* Gram negative bacilli included coliforms (n=7), mixed anaerobes (n=2), *Proteus* species (n=1), *Pseudomonas aeruginosa* and *Aeromonas* species (n=1)
142 References


